Firouz Mohsenian

Firouz Mohsenian has extensive experience in the field of research and development in the biotechnology industry. From 2021 to the present, they have worked at Capricor Therapeutics, Inc., first as a Senior Scientist and then as a Research Manager in Cell Biology. In these roles, they focused on the development of exosome-derived molecular therapies and the scale-up and manufacturing of cardiosphere-derived cells.

Prior to their time at Capricor Therapeutics, Inc., Firouz worked as a Research Scientist at BPS Bioscience Inc. from 2020 to 2021, where they conducted research in the field of bioscience.

From 2011 to 2019, Firouz was employed at Intrexon Corporation as a Scientist in the Cell Engineering Unit. In this role, they led a team and developed various cell and molecular based assay developments with a focus on human therapeutics and cell replacement therapies.

Before joining Intrexon Corporation, Firouz worked at GenMark Diagnostics in 2010 as a Scientist in Research and Development. Firouz also worked at Cyntellect, Inc. from 2009 to 2010 as a Research Associate III in Applications Development.

From 2007 to 2009, Firouz was a Senior Research Associate in Diagnostics Development at Sequenom, Inc. Here, they were involved in the development of the MaterniT21 NIPT Kit, the first non-invasive prenatal test kit used for Fetal Trisomy detection.

Additionally, Firouz has worked at Cytori Therapeutics Inc. from 2005 to 2007 as a Research Associate II in the Department of Research and Technology, and at The Salk Institute for Biological Studies from 2004 to 2005 as a Research Assistant II in the Laboratory of Genetics, Gage Lab. In these roles, they conducted molecular biology research on neural stem cells and neurogenesis, and also worked on projects related to the protection of cells from apoptosis and the improvement of memory and psychomotor functions.

Firouz Mohsenian has attended San Diego State University. However, no specific details regarding the degree, field of study, or the start and end years are provided.